Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 11/20 | 0.47 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2515945 | 1.00 | HRH2 (0.47) | HRH2HRH1SLC6A5KDM4DDRD4 | |
| SCHEMBL5254458 | 1.00 | HRH2 (0.47) | HRH2HRH1SLC6A5KDM4DDRD4 | |
| SCHEMBL5253779 | 1.00 | HRH2 (0.47) | HRH2HRH1SLC6A5KDM4DDRD4 | |
| SCHEMBL2513583 | 0.96 | HRH2 (0.49) | HRH2HRH1SLC6A5KDM4DDRD4 | |
| SCHEMBL2513364 | 0.96 | HRH2 (0.49) | HRH2HRH1SLC6A5KDM4DDRD4 | |
| SCHEMBL2517954 | 0.96 | HRH2 (0.49) | HRH2HRH1SLC6A5KDM4DDRD4 | |
| SCHEMBL5254023 | 0.96 | HRH2 (0.49) | HRH2HRH1SLC6A5KDM4DDRD4 | |
| SCHEMBL5255067 | 0.93 | NPC1 (0.49) | HRH2HRH1SLC6A5KDM4DDRD4 | |
| SCHEMBL2515970 | 0.93 | NPC1 (0.49) | HRH2HRH1SLC6A5KDM4DDRD4 | |
| SCHEMBL2515968 | 0.93 | NPC1 (0.49) | HRH2HRH1SLC6A5KDM4DDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | claimed |
| EP-1748980-A1 | PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-07 | — | — | EP | claimed |
| WO-2005115977-A1 | PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 2005-12-08 | — | — | WO | claimed |
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1748980-A1 | PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005115977-A1 | PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | CNR1, CNR2, OPRD1 | HRH2 15/4885HRH1 12/4885SLC6A5 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.